Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors
The Prostate · 2026-08 · 86 (11) · 1187-1194
DOI: 10.1002/pros.70197 ↗At a glance
Journal article in The Prostate, published online on 2026-05-26. Written by Ondřej Fiala and 11 co-authors. Institution: Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Major MEDLINE topics: Phosphopyruvate Hydratase, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Univerzita Karlova v Praze, Fakultní Nemocnice Plzen, European Union's Horizon.
Abstract (original language)
Background
Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Methods
We retrospectively analyzed ARSI‐treated mCRPC patients with available baseline NSE (n = 120). NSE was dichotomized by the upper limit of normal (ULN, 12.5 ng/mL). Radiographic progression‐free survival (rPFS) and overall survival (OS) were estimated by Kaplan–Meier methods and compared by log‐rank test. Multivariable Cox models adjusted for age, baseline PSA (per 100 ng/mL), line of therapy (2–4 vs 1), Gleason score (> 7 vs ≤ 7), metastatic timing (synchronous vs metachronous), and visceral metastases (present vs absent). NSE dynamics were evaluated using a 28‐day landmark approach among patients alive and at risk at day 28 with available baseline and week‐4 NSE (rPFS landmark n = 47; OS landmark n = 48); follow‐up was redefined from day 28 and dynamics were modeled as log2(NSE 4w /NSE 0 ) (per doubling).
Results
Median follow‐up was 44.7 months (95% CI 35.7–48.3). Baseline NSE > ULN was associated with shorter rPFS (9.4 vs 20.8 months) and OS (23.5 vs 38.2 months). In multivariable analyses, baseline NSE > ULN remained independently associated with inferior outcomes (rPFS HR 1.81, 95% CI 1.15–2.85, p = 0.011; OS HR 1.85, 95% CI 1.12–3.05, p = 0.017). In landmark models, higher NSE dynamics were independently associated with worse outcomes (rPFS HR 4.30, 95% CI 1.06–17.39, p = 0.041; OS HR 8.78, 95% CI 2.15–35.77, p = 0.002).
Conclusions
In ARSI‐treated mCRPC, baseline NSE above ULN and early 4‐week NSE dynamics provide independent prognostic information for rPFS and OS, supporting NSE as a pragmatic adjunct to clinical risk stratification.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- ARON Research Foundation ETS, Macerata, Italy.
- Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- Department of Surgery, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- Oncology Unit, Macerata Hospital, Macerata, Italy.
ORCID profiles: Ondřej Fiala, Milan Hora
Funding
- Univerzita Karlova v Praze
- Fakultní Nemocnice Plzen
- European Union's Horizon
- Toyohashi University of Technology
Cite
APA
Fiala, O., Tkadlecová, M., Váchalová, Z., Hora, M., Králíček, J., Stránský, P., Liška, V., Santoni, M., Banna, G. L., Pivovarčíková, K., Topolčan, O., & Fínek, J. (2026). Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate, 86(11), 1187-1194. https://doi.org/10.1002/pros.70197
Vancouver
Fiala O, Tkadlecová M, Váchalová Z, Hora M, Králíček J, Stránský P, et al. Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate. 2026;86(11):1187-1194. doi:10.1002/pros.70197
BibTeX
@article{Fiala2026,
author = {Fiala, Ondřej and Tkadlecová, Michaela and Váchalová, Zuzana and Hora, Milan and Králíček, Jan and Stránský, Petr and Liška, Václav and Santoni, Matteo and Banna, Giuseppe Luigi and Pivovarčíková, Kristýna and Topolčan, Ondřej and Fínek, Jindřich},
title = {Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {11},
pages = {1187--1194},
doi = {10.1002/pros.70197}
}
EUVIMED